Clinical Trial Update: ALD-301 for Critical Limb Ischemia, Randomized Trial [Phase 1, Phase 2]

View source ↗

Summary

ALD-301 was evaluated in a randomized Phase 1/2 trial for critical limb ischemia and peripheral arterial disease. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Critical Limb Ischemia
• Peripheral Artery Disease
• Peripheral Vascular Disease

Drugs mentioned

• ALD-301

Snippet

Sponsor: Aldagen | Conditions: Critical Limb Ischemia, Peripheral Arterial Disease | Phase 1, Phase 2 | Status: COMPLETED